Evidence map›Paper›PMID 41987768›Full record

ArticleFrontiers in medicine2026

Guselkumab is effective in the treatment of Inverse psoriasis: a case report and literature review.

Zhuochen Wu, Xiaoyu Xie, Wenyu Tang, Yifeng Wu, Guoqiang Zhang, Qing Zhu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhuochen WuDepartment of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xiaoyu XieDepartment of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Wenyu TangThe Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yifeng WuAffiliated Hospital of Hebei Engineering University, Handan, Hebei, China.
Guoqiang ZhangDepartment of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Qing ZhuDepartment of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inverse psoriasis is a special type of psoriasis whose pathogenesis is not yet fully understood, and for which there is no consensus guideline due to marked therapeutic challenges associated with the specific anatomic location of lesions. Immune-mediated inflammation plays a key role in its development, and the lesions are susceptible to friction and humidity, which makes the affected area less tolerant to treatment. In this article, we report a successful case of Inverse psoriasis treated with Guselkumab in a 48-years-old male, who was treated with three subcutaneous injections of Guselkumab and exhibited marked improvement in cutaneous lesions and pruritus at 12 weeks of treatment. A review of the relevant literature was also conducted with the aim of providing clinicians with more references for the treatment of this disease.

Indexed as

biologicsclinical efficacyGuselkumabinterleukin-23 inhibitorInverse psoriasis

Identifiers

PMID41987768
PMCPMC13076470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.